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Primary familial brain calcification (PFBC) is a rare neurodegenerative disorder characterized by a combination of neurological, psychi-
atric, and cognitive decline associated with calcium deposition on brain imaging. To date, mutations in five genes have been linked to
PFBC. However, more than 50% of individuals affected by PFBC have nomolecular diagnosis. We report four unrelated families present-
ing with initial learning difficulties and seizures and later psychiatric symptoms, cerebellar ataxia, extrapyramidal signs, and extensive
calcifications on brain imaging. Through a combination of homozygosity mapping and exome sequencing, we mapped this phenotype
to chromosome 21q21.3 and identified bi-allelic variants in JAM2. JAM2 encodes for the junctional-adhesion-molecule-2, a key tight-
junction protein in blood-brain-barrier permeability. We show that JAM2 variants lead to reduction of JAM2 mRNA expression and
absence of JAM2 protein in patient’s fibroblasts, consistent with a loss-of-function mechanism. We show that the human phenotype
is replicated in the jam2 complete knockout mouse (jam2 KO). Furthermore, neuropathology of jam2 KO mouse showed prominent
vacuolation in the cerebral cortex, thalamus, and cerebellum and particularly widespread vacuolation in the midbrain with reactive as-
trogliosis and neuronal density reduction. The regions of the human brain affected on neuroimaging are similar to the affected brain
areas in the myorg PFBC null mouse. Along with JAM3 and OCLN, JAM2 is the third tight-junction gene in which bi-allelic variants
are associated with brain calcification, suggesting that defective cell-to-cell adhesion and dysfunction of the movement of solutes
through the paracellular spaces in the neurovascular unit is a key mechanism in CNS calcification.Primary familial brain calcification (PFBC [MIM: 213600]),
often referred as Fahr disease, constitutes a heterogeneous
neurodegenerative disorder that presents with mineral
calcium deposits in the brain. The clinical manifestations
can include, but are not restricted to, movement disorders
such as parkinsonism and ataxia, seizures, migraine, and
neuropsychiatric symptoms. Both autosomal-dominant
and -recessive inheritance patterns have been reported.1
The clinical picture and severity are often variable be-
tween and within families, with some family members be-
ing clinically asymptomatic. The advent of widespread
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significantly increased the number of PFBC-affected fam-
ilies identified.2
There are two main pathogenic mechanisms described
so far in PFBC. On the one hand, the calcium and phos-
phate homeostasis dysfunction via dominant mutations
in SLC20A2 (MIM: 158378) and XPR1 (MIM: 605237).1
The inhibition of phosphate uptake by mutations in
SLC20A2 encoding for sodium-dependent phosphate
transporter 2 (PiT-2) leads to deposition of calcium in the
vascular extracellular matrix, and inhibition of phosphate
export associated with XPR1 mutations is expected torology, Queen Square, WC1N3BG London, UK; 2Dubowitz Neuromuscular
on, UK; 3Argentine National Scientific and Technological Research Council
Institute, C1428 AQK Buenos Aires, Argentina; 4Department of Clinical and
3BG London, UK; 5Division of Neuropathology, The National Hospital for
dation Trust, Queen Square, London WC1N 3BG, UK; 6Department of Pedi-
gy, Dublin Neurological Institute at the Mater Misericordiae University Hos-
e, Royal Victoria Hospital, Belfast BT12 6BA, UK; 9Neurology Centre, South-
nt of Neurodegenerative Disease, UCLQueen Square Institute of Neurology,
eaching Hospitals NHS Trust, Leeds General Infirmary, Leeds LS1 3EX, UK;
on WC1N 3BG, UK; 13Universidade Federal de Pernambuco, Departamento
m, CNRS, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France; 15CEN-
ical Faculty & AGENTEM (Adana Genetic Diseases Diagnosis and Treatment
way, Gaithersburg, MD 20877, USA; 18Centre for Cancer Research and Cell
nd Clinical Service, The National Hospital for Neurology and Neurosurgery,
5, 2020
ttp://creativecommons.org/licenses/by/4.0/).
Figure 1. Clinical and Neuroimaging Features of JAM2-Related Disease
(A) Pedigrees of the four families with bi-allelic JAM2 mutations.
(B) Brain images of JAM2-related disease. B1 to B3 are CT scans acquired from case subject F1-II:2 from family 1 and B4 to B6 are CT ac-
quired from case subject F2-III:3 from family 2. In both individuals there is extensive, symmetrical, bilateral calcification involving the
(legend continued on next page)
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increase intracellular phosphate concentration and pro-
voke calcium phosphate precipitation.3
On the other hand, the second mechanism causes PFBC
through disruption of the neurovascular unit (NVU).
Endothelial integrity and function affecting the blood-
brain barrier (BBB) is altered via dominant mutations in
PDGFB (MIM: 190040) and PDGFRB (MIM: 173410) encod-
ing for the platelet-derived growth factor B and its receptor,
that lead to the impairment of pericytes recruitment and
BBB integrity, causing vascular and perivascular calcium
accumulation.2 The recessive brain calcification pheno-
type due to MYORG4 (MIM: 618255) mutations, has been
shown to present specific myorg mRNA expression in
mouse astrocytes and disturb the normal function of the
NVU. Mutations in JAM35 (MIM: 613730) and OCLN6
(MIM: 602876) encoding for tight junction proteins lead
to excess solutes crossing the BBB causing CNS calcifica-
tion and hemorrhage.
Interestingly, a study on the Slc20a2 null mouse sug-
gested that the calcified nodules present in the brain initi-
ated in pericytes and astrocytes and found endogenous IgG
around nodules proposing that there was increased BBB
permeability7 and identifying a possible link between
different PFBC causative genes.
Pathologically, human brains exhibit calcium salt de-
posits predominantly distributed around small blood ves-
sels,2 and a reported subject with a SLC20A2mutation pre-
sented calcification in the tunica media of small arteries,
arterioles, and capillaries, but not in veins distributed in
the basal ganglia, thalamus, cerebellar white matter, and
deeper layers of the cerebral cortex.8
Despite important progress in discovering the genetic ar-
chitecture of PFBC, more than half of the case subjects
remain genetically unsolved.2
In this study we report four unrelated families with
seven individuals affected by autosomal-recessive primary
familial brain calcification. In the families described here,
we used a combination of homozygosity mapping, exome
sequencing (ES), functional studies, and mouse model to
identify and characterize the causal variants in JAM2
(MIM: 606870) encoding for the junctional-adhesion-
molecule-2, a tight-junction protein as a cause of PFBC.
Two unrelated consanguineous families from traveller
communities in England (family 1) and Northern Ireland
(family 2), one non-consanguineous family from the
United States (family 3) identified using GeneMatcher,
and one Turkish consanguineous family (family 4) were
included in this study (Figure 1A). Clinical features of
affected individuals are presented in Table 1. The proband
in family 1 (F1-II:2) had a normal birth and early mile-
stones. He presented with childhood-onset cerebellar
ataxia and learning difficulties. His symptoms progressedbasal ganglia, deep cortical gray matter and cerebellum. B7, 8, and 9
basal ganglia and cortical gyri but not in the cerebellum. B10, 11, a
showing basal ganglia and frontal calcification (B10 is T1 MRI, B11 is
sitive to calcium shown as hypointense regions). Asterisk (*) areas of
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and worsening cognitive impairment. He was examined
by a neurologist at the age of 23 years old. At that stage,
he already had difficulties following commands and had
alternate exotropia with left eye preference for fixation,
slow and jerky pursuit, and ophthalmoplegia. He had
reduced ability to control tongue movements and was un-
able to protrude his tongue. He was dysarthric with
dysphagia and a percutaneous endoscopic gastrostomy
(PEG) insertion at the age of 22 years. He had increased
tone in the upper and lower limbs with ankle contractures,
brisk reflexes throughout, and upgoing plantars. There was
upper and lower limb ataxia, bradykinesia, and generalized
dystonia, worse in the upper limbs (Video S1). Occasional
seizures were seen later in the disease course. The interictal
electroencephalography (EEG) showed moderate general-
ized slowing of cortical rhythms.
There were four affected individuals in the second fam-
ily. Two siblings (F2-III:2 and F2-III:3) presented with
borderline low IQ in childhood but had no definite phys-
ical limitations in early life. In their twenties they had so-
cial withdrawal and severe depression requiring treatment.
The disease progressed and examination at 41 and 39 years
revealed severe speech hypophonia, dysphagia, hypomi-
mia, reduced vertical up gaze, orofacial dyskinesias, slow
and reduced tongue movements with bradykinesia, and
dystonic limb posturing in both affected individuals.
Tone was increased in an extrapyramidal pattern with
lower limb hyperreflexia and extensor plantar responses,
grasp reflexes, positive glabellar tap, and brisk jaw jerk.
They both hadmemory decline with impaired recall. Treat-
ment with ropinirole did not lead to any significant
improvement in symptoms. The disease progressed, they
became bedridden and case F2-III:2 needed a PEG insertion
10 years after the onset of movement problems due to
recurrent aspiration pneumonia, and the proband died in
the late 40s. Case subjects F2-III:4 and F2-III:5 are maternal
first cousins of the index case subject in family 2. They pre-
sented an almost identical phenotype. On a background of
depression, both brothers noted progressive ‘‘slurring’’ of
speech, slowing of all movements, difficulty with walking,
recurrent falls, and poor memory. Examination demon-
strated a similar phenotype with dysarthria, abnormal pur-
suit with frequent saccadic intrusions, pronounced brady-
kinesia, extrapyramidal rigidity, and bilaterally extensor
plantar responses.
The proband in family 3 (F3-II:1) had normal early devel-
opment but later developed mild delay in fine motor and
language milestones that were progressive. He also devel-
oped mild coordination problems and autism spectrum
disorder (ASD) and received special education services at
school age. At age 11 years, repeat neuropsychologicare CT from case subject F3-II:1 demonstrating calcification in the
nd 12 are axial MRI scans from individual F3-II:1 from family 3
T2 MRI, and B12 is Axial Ven Bold reconstruction MRI that is sen-
calcification on MRI.
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Table 1. Clinical Features of Affected Individuals with JAM2 Bi-allelic Variants
Individual
F1-II:2
Individual
F2-III:2
Individual
F2-III:3
Individual
F2-III:4
Individual
F2-III:5
Individual
F3-II:1
Individual
F4-II:3
cDNA sequence c.685C>T c.685C>T c.685C>T c.685C>T c.685C>T c.3951dupG,
c.323G>A
c.177_180delCAGA
Amino acid change p.Arg229Ter p.Arg229Ter p.Arg229Ter p.Arg229Ter p.Arg229Ter IVS4-1dupG,
p.Arg108His
p.Arg60Ter
Zygosity homozygous homozygous homozygous homozygous homozygous compound
heterozygous
homozygous
Gender (male/female) male male female male male male female
Birth and early milestones normal normal normal normal normal normal normal
Onset of symptoms childhood late 20s late 30s teenage teenage childhood early childhood
Symptom at onset cerebellar ataxia and
cognitive decline
cognitive decline,
depression
difficulty walking depression, dysarthria depression, dysarthria autism spectrum
disorder
seizures
Age at examination
(in years)
24 41 39 40 49 15 7
Phenotype at Last Examination
Pyramidal syndrome yes; increased tone,
brisk reflexes,
upgoing plantars
yes; increased tone,
brisk reflexes,
upgoing plantars
yes; increased tone,
brisk reflexes,
upgoing plantars
yes; increased
tone, brisk
reflexes, upgoing
plantars
yes; increased tone,
brisk reflexes,
upgoing plantars
no no
Cerebellar syndrome yes; upper and
lower limb ataxia,
dysarthria, nystagmus
yes; upper and
lower limb ataxia
yes; upper and
lower limb ataxia
yes; upper and
lower limb
ataxia, dysarthria
yes; upper and
lower limb
ataxia, dysarthria
yes; upper and
lower limb mild
ataxia, nystagmus
no
Parkinsonism yes; rigidity,
bradykinesia.
yes; hypophonia,
hypomimia,
bradykinesia
yes; hypophonia,
hypomimia,
bradykinesia
yes; rigidity,
bradykinesia
yes; rigidity,
bradykinesia
no no
Dystonia yes; generalized yes; limb dystonia
and orofacial
dyskinesias
yes; limb dystonia
and orofacial
dyskinesias
no no no no
Other seizures, ophthalmoplegia,
PEG inserted in advance
stage
PEG inserted in
advance stage
became anarthric
in advanced
stage
– – autism spectrum
disorder
–
Cognitive function severe cognitive decline memory decline
with severe
impaired recall
unable to comment
on cognition
due to anarthria.
severe cognitive
decline
severe cognitive
decline
decline in
academic
performance
normal for her age
Brain imaging calcification
pattern
basal ganglia, thalamus,
cerebellum, deep gray
matter
basal ganglia,
thalamus,
cerebellum, deep
gray matter
basal ganglia,
thalamus,
cerebellum,
deep gray matter
basal ganglia,
thalamus,
cerebellum,
deep gray matter
basal ganglia,
thalamus,
cerebellum,
deep gray matter
basal ganglia,
and frontal
cortex
basal ganglia,
dentate nucleus
and cerebellar
hemispheres
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evaluation showed a continuous decline in academic per-
formance. Parents were asymptomatic, an older brother
had some anxiety and hyperactivity, and a younger
brother aged 13 years had mild autistic features. At the
last examination of the proband aged 15 years, he had
autism spectrum features, hyperactivity, developmental
delay, and coordination problems. The coordination diffi-
culties were mild but affected both fine motor skills (but-
tons, zippers, hooks) and complex gross motor tasks. His
learning difficulties were progressive.
The affected member of family 4 (F4-II:3) was born to
Turkish consanguineous parents and presented with sei-
zures when she was 18 months of age; current age is 7.5
years and she has had a total of 3 seizures. Her develop-
ment so far has been in keeping with her peers and her
last examination did not reveal any neurological signs.
Brain calcification was identified on MRI imaging with
bilateral symmetric calcification of the basal ganglia, den-
tate nucleus, and subcortical white matter of cerebellar
hemispheres. Prior to exome sequencing, the known Fahr’s
genes was sequenced and negative.
All seven case subjects reported here had brain calcifica-
tion identified on brain CT and/or MRI imaging. They had
a consistent pattern of bilateral symmetric calcification of
the basal ganglia and deep cortical graymatter. In addition,
the older individuals from families 1 and 2 had severe calci-
fication in the cerebellum folia and the thalamus
(Figure 1B). All families had extensive genetic, metabolic,
and mitochondrial investigations carried out that
excluded acquired and other inherited causes of brain
calcification.
In order to localize the chromosomal location of
the pathogenic variant, we genotyped three affected
and two unaffected individuals from extended family
2 genome-wide by using Illumina HumanCytoSNP-12v2-
1 Beadchip array incorporating 200,000 genetic markers.
Three regions of homozygosity were detected on
chr10:37,414,883–43,132,376, chr13:88,327,643–93,518,
692, and chr21:22,370,881–28,338,710. Next, we per-
formed exome sequencing on probands of families 1 and
2 to identify the causative variant(s). On the assumption
that the disease follows an autosomal-recessive pattern
of inheritance in the families as well as presence of consan-
guinity in two families, we prioritized the bi-allelic
potentially functional variants residing within the runs
of homozygosity. These variants were screened through
all publicly available population databases and our in-
house database. We excluded synonymous variants,
intronic variants (>7 bp from exon boundaries) and com-
mon variants (minor allele frequency > 0.001%). The
selected variants were validated, and segregation analysis
was performed using Sanger sequencing.
In families 1 and 2, filtered exome-sequencing data nar-
rowed down the variants to the same homozygous
nonsense variant (GenBank: NM_021219; c.685C>T
[p.Arg229Ter]) in JAM2 residing within a 5 Mb region of
homozygosity on chr21q21.3 (Figure S1). Sanger416 The American Journal of Human Genetics 106, 412–421, Marchsequencing verified the correct segregation of the variant
on available samples of both families (Figures 1A, 2A,
and 2B). This variant was absent in our in-house exome
database of more than 10,000 exomes, absent in homozy-
gous state in all publicly available databases, and present in
heterozygous state with a minor allele frequency (MAF) of
0.00002 in gnomAD (6/280662). The early stop codon
introduced by c.685C>T is predicted to result in produc-
tion of a truncated protein lacking the transmembrane
and cytoplasmic regions of JAM2 and cause reduction in
total JAM2 as a consequence of nonsense-mediated decay
(NMD) of the mutant transcript. Indeed, RT-PCR analysis
confirmed a reduction of JAM2 mRNA expression levels
in the proband in family 1 compared to the heterozygous
carrier and unrelated control subject (Figure 2C). Further-
more, western blot analysis confirmed the absence of
JAM2 protein in the homozygous proband (Figure 2D).
The reduction of RNA expression and absent JAM2 protein
in the fibroblast cell lines of the proband support the loss-
of-function role of this variant. As JAM2, JAM3, and TJP1
proteins are all junctional components and associated
with brain calcification phenotype, we investigated
whether JAM2 c.685C>T variant affected the localization
of the other two proteins. We show that there was no dif-
ference in the localization of JAM3 and TJP1 in primary
dermal fibroblasts from JAM2 homozygous affected indi-
viduals (Figure S2).
In family 3, Trio-ES revealed compound heterozygous
variants in JAM2 (GenBank: NM_021219; c.3951dupG
[IVS4-1dupG] and c.323G>A [p.Arg108His]). The
c.3951dupG was inherited from the father and
c.323G>A was inherited from the mother. The c.323G>A
was reported once in gnomAD in heterozygous state
(MAF 0.00003, 1/31408), three times in GeneDx in-house
database (MAF 0.00002, 3/167854), and was absent in all
databases as homozygous. It disrupts a highly conserved
residue (CADD:34) and is predicted to be damaging to
the protein function by in silico prediction tools (SIFT,
PROVEAN, Mutation Taster, Mutation Assessor, and Poly-
Phen). The c.3951dupG is predicted to cause the reten-
tion of the canonical splice acceptor site of intron 4 with
insertion of the G nucleotide as the first base of exon 5
causing a frameshift and a truncated protein (p.Val132-
GlyfsX9). This variant was absent from all public databases
and present five times in heterozygous state in GeneDx in-
house database (MAF 0.00003, 5/171284). The variants
segregated fully within the family (Figures 1A, 2A, and 2B).
In family 4, clinical ES uncovered a homozygous 4 bp
deletion in JAM2 (GenBank: NM_021219; c.177_180del-
CAGA [p.Arg60Ter]) (Figures 1A, 2A, and 2B) that causes
a frameshift and an early termination of the protein
affecting the extracellular, transmembrane, and cyto-
plasmic domains of JAM2. The variant was not reported
in any public databases and was predicted pathogenic by
MutationTaster causing loss of function by NMD.
In order to characterize the link between JAM2 variants
and the human neurological phenotype, we developed5, 2020
Figure 2. Validation of JAM2 Variants
Identified in This Study
(A) Validation by Sanger sequencing of the
stop variant c.685C>T (p.Arg229Ter) in
families 1 and 2, the bi-allelic variants in
family 3 (IVS4-1dupG and p.Arg108His),
and the homozygous change in family 4
c.177_180delCAGA (p.Arg60Ter).
(B) Protein structure of JAM2 showing the 2
main domains (Ig-like V-type and Ig-like C2-
type) as well as the variants identified in the
4 families.
(C) Total RNA and protein extracts were pre-
pared from fibroblast cell lines isolated from
the proband of family 1 (HOM), his unaf-
fected mother (HET), and unrelated control
subjects (Con) to assess the c.685C>T
(p.Arg229Ter) JAM2 variant. Agarose gel sep-
aration of RT-PCR products shows a reduc-
tion in JAM2 mRNA expression in the ho-
mozygous proband (HOM) compared to
the proband’s mother (HET) and unrelated
control subject (Con). GAPDH RT-PCR
served as a loading control.
(D) Western blot analysis of total protein ly-
sates using anti-JAM2 and GAPDH (loading
control) antibodies revealed presence of
JAM2 protein in control (Control) and unaf-
fected carrier (HET) cells but complete loss
of JAM2 protein in the homozygous pro-
band of family 1 (HOM). NS, non-specific
band; asterisk, JAM2.jam2 knockout (jam2 KO) mice. Behavioral tests in the
jam2 KO mice showed significant difficulties in beam
walking test and gait abnormalities when compared to
wild-type mice (Figure 3). There was a significant reduction
in stride length (wild-type: 8.145 0.9, jam2 KO: 6.3 5 1;
***p< 0.0001) and increase in sway length (wild-type: 0.13
5 0.14, jam2 KO: 0.95 0.4; **p ¼ 0.002) when comparing
jam2 KO to wild-type littermates’ controls (Figure 3A).
Additionally, the number of missed steps (wild-type: 1.2
5 1.3, jam2 KO: 6.5 5 3.6; *p ¼ 0.017) in the beam-
walking test was higher in jam2 KO compared to controls
(Figure 3B and 3C, Video S2).
Brains of two jam2 KO and two wild-type (C57BL/6)
mice were examined at a young age (6 months old) and
four jam2 KO and four wild-type mice were examined at
an old age (18 months old). In addition, spinal cord sec-
tions from one of the young jam2 KO mice and from all
old jam2 KO and control mice were examined. We
observed prominent widespread vacuolation in the
midbrain and some in the thalamus and cerebral and cere-The American Journal of Humanbellar cortex of young jam2 KO mice.
In the midbrain, the vacuolar change
was accompanied by prominent reac-
tive astrogliosis, mild microglial activa-
tion, and mild reduction in the
neuronal density compared to controls
(Figure 4). Brains of aged jam2 KOmice
showed similar changes, with promi-nent widespread neuropil vacuolation in the midbrain
accompanied by marked astrogliosis, mild microglial acti-
vation, and moderately reduced neuronal density. In
contrast to young jam2 KO mice, there was more promi-
nent vacuolation in the cerebral cortex, thalamus, and
cerebellar cortex and particularly widespread vacuolation
in the cerebellar white matter. To a lesser extent, neuropil
vacuolation in the same regions was also seen in the age-
matched control wild-type mice, suggesting that jam2
KO mice develop age-related changes at a much younger
age, which in some areas, such as cerebellar white matter,
midbrain, thalamus, and cerebellar cortex, increase in
severity with age. In addition, we performed automated
quantification of the neuropil vacuolation on H&E-stained
sections, GFAP immunoreactive gliosis and Iba1-positive
microglial activation in young and aged wild-type and
jam2 KO mice (Figure S3). Automated quantification of
the percentage of vacuolation, gliosis, and microglial acti-
vation in the cortex, midbrain, and cerebellum was per-
formed on digitalized slides, using open source softwareGenetics 106, 412–421, March 5, 2020 417
Figure 3. Behavioral Study on jam2 KO
Mice and Wild-Type (WT)
(A) Representative images of wild-type (left)
and jam2 KO strides (right) in the gait test.
Forepaw (blue) and hindpaw (red). Altered
gait of the jam2 KO mice was analyzed in
stance length, stride, and sway compared
to wild-type (***p < 0.0001, **p ¼ 0.002;
means5 SEM; n ¼ 6 mice per genotype).
(B and C) Walking beam performance on
test day, showing elevated latency to cross
the beam in jam2 KO (*p ¼ 0.017; means
5 SEM; n ¼ 5 wild-type, n ¼ 6 jam2 KO).
See Video S2 for example beam walking
test of a jam2 KO mouse and a control
(wild-type).QuPath. There was a significant increase in the degree of
neuropil vacuolation (p < 0.00007) and astrogliosis (p <
0.0138) in the midbrain of old jam2 KO mice when
compared with age-matched wild-type mice, whereas
Iba1-positive microglial activation in old jam2 KO mice
was less pronounced than in age-matched wild-type mice
(p < 0.035). No mineralization or calcification was
observed in the brains of young or old jam2 KO mice or
controls at the time of examination.
The spinal cord morphology was similar in young and
old jam2 KO-deficient mice but remarkably differed from
that of control mice. The main findings in jam2 KO spinal
cords were widespread neuronal, perivascular, and neuro-
pil mineralization as well as widespread vacuolation in
the gray matter. The mineralized deposits were negative
for PAS and showed weak reactivity for Alcian blue,
excluding calcification, cartilagination, or ossification
stage. The mineralization and vacuolar change were
evident across the gray matter in both anterior and poste-418 The American Journal of Human Genetics 106, 412–421, March 5, 2020rior horns bilaterally and at all levels of
the spinal cord. Although mineraliza-
tion and calcification are known to
occur with age in wild-type mice, in
the four spinal cords from our control
group (age-matched to old jam2 KO
mice), no mineralization or neuropil
vacuolation at any of the spinal cord
levels was observed (Figure S4). JAM3
and TJP1 tight-junction proteins were
investigated in the KO mice, and there
was no difference in localization be-
tween affected and wild-type mice, in
different areas of the brain (Figures S5
and S6).
Mouse models of other brain calcifi-
cation genes have shown brain calcifi-
cation in similar areas to those found
in humans. Such is the case of
Slc20a2-null mice exhibiting progres-
sive calcification of the thalamus, basal
ganglia, and cortex beginning at8 weeks and present in close proximity or within blood ves-
sels and affecting astrocytes and perycites7,9,10 and for my-
org-null mice developing calcifications at 9 months.4 A
study on mice carrying hypomorphic Pdgfb alleles interest-
ingly showed that the calcifications depend on the loss of
endothelial PDGF-B and correlate with the degree of peri-
cyte and BBB deficiency.11 Ocln-null mice present with
similar calcification surrounding blood vessels as seen in
an autopsied case,6 but there were no abnormalities re-
ported in the brain of jam3 KOmice, and there was absence
of Jam3 in the vasculature of the adult mouse brain.5 In our
study, we were not able to detect calcification in the brain of
our jam2 mouse model even though we studied these mice
until the age of 18 months, an age at which other PFBC
models already present calcification and thus it does not
seem to be age related. However, our jam2 KO mice did
show prominent vacuolation, inflammatory response, and
neuronal density reduction in the same areas affected by
calcification in humans. Further studies are needed to
Figure 4. Brain Pathology in Control and jam2 KO Mice of Young (6 Months Old) and Old Age (18 Months Old)
Littermate controls (wild-type) (a, a1–a6) show no significant pathology on (H&E) stained sections (a, cortex; a1, cerebellum; a2,
midbrain) and on immunohistochemistry for astrocytes (GFAP) (a3, midbrain), microglia (Iba1) (a4, midbrain), neuropil (APP) (a5,
midbrain), and neurones (NeuN) (a6, midbrain). In age-matched jam2 KOmice, occasional cortical vacuolation is evident in the cerebral
(b) and cerebellar (b1) cortex and widespread prominent vacuolation is seen in the midbrain (b2). In the midbrain region there is also
marked reactive astrocytosis (b3) and mild microglial activation (b4). APP immunostaining highlights vacuolar change in the neuropil
(b5) and NeuN shows mild reduction in the neuronal density (b6). Aged wild-type mice show occasional vacuolation in the cerebral
(legend continued on next page)
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understand better the disease mechanisms and the differ-
ences between humans and mice for JAM2 and also JAM3.
Together, our results confirm that JAM2 variants underlie
the phenotype in the four families reported here. This im-
plicates JAM2 as a cause of human Mendelian disease.
JAM2 encodes for the junctional-adhesion-molecule-2
(JAM2), member of the junctional adhesion molecules
family, localized in the tight junctions of endothelial cells
and the NVU.12,13 JAM2 is an adhesive ligand interacting
with various immune cell types and regulating vascular
function and was recently identified as an inhibitor of
somatodendritic myelination in spinal cord neurons.14
Junctional adhesion molecules are a family of proteins
that play an important role in the regulation of cell polar-
ity, endothelium permeability, and leukocyte migration
and the blood-brain-barier (BBB) function. In addition to
JAM2, recessive variants in JAM3 and OCLN were linked
to complex neurological disorders presenting with calcifi-
cation in the brain,5,6 suggesting that deregulation of the
central NVU is important in pathogenesis of PFBC. Even
though increased permeability of the BBB hasn’t been
confirmed in jam2 KO mice so far,13 including this study,
mutations have now been identified in three genes encod-
ing tight junction proteins in humans (JAM2, JAM3, and
OCLN), suggesting that loss of cell-to-cell adhesion with
subsequent dysfunction of solute passage is an important
cause of brain calcification. Furthermore, a multicenter
collaboration from China recently described four patients
from three families that presented with PFBC and bi-allelic
mutations in JAM2.15 They interestingly show failure of
JAM2 to translocate to the plasma membrane in JAM2
transfected mutants of hamster ovary cells, and they pro-
pose a cell-to-cell adhesion impairment as the mechanism
causing failure of the NVU and consequent brain calcifica-
tion phenotype. This work further supports our hypothesis
and together with PDGFB, PDGFRB, and MYORG the tight
junction genes solidify dysregulation of BBB integrity as a
key PFBC pathomechanism (Figure S7).
Importantly, we show that the human JAM2-related
neurological phenotype seen is replicated in the jam2 KO
mouse. It is noteworthy that the older human individuals
carrying JAM2 variants, who had longer disease duration,
presented impaired gait of variable severity including
ataxic and/or parkinsonian gait illustrated in the mouse
model. The main walking and behavioral findings in the
affected mice were progressive gait abnormalities, similar
to ataxic mouse, clearly seen on standard mouse pheno-
type assessment. Furthermore, neuropathology of jam2
KO mouse model (prominent vacuolation in the cerebral
cortex, thalamus, and cerebellar cortex and particularlycortex (c), cerebellar cortex (c1), and midbrain (c2) (H&E). There is
activation (c4). No significant disruption of the cytoarchitecture is see
of neuronal loss (c6). In age-matched old jam2 KOmice, there is incre
cerebellar white matter (d1), midbrain (d2), and thalamus (not shown
in the midbrain (d3), but microglial activation remains mildly increa
APP immunostaining (d5). Similar to age-matched littermate controls
KO mouse (d6). Scale bar: 100 mm in a–d, a2–a6, b2–b6, c2–c6, d2–d
420 The American Journal of Human Genetics 106, 412–421, Marchwidespread vacuolation in the midbrain) affected similar
brain areas to those observed on brain imaging of the hu-
man phenotype. The pattern of calcification seen on the
brain scans of our subjects was largely the same as that
seen in PFBC-affected subjects where the brain is structur-
ally normal and the calcification is almost exclusively in
the gray matter affecting basal ganglia, thalamus, deep cor-
tex, dental, and cerebellar folia.16 It was indistinguishable
from SLC20A2, PDGFB, PDGFRB, and XPR1 case subjects
and there was no calcification in the pons as seen in MY-
ORG subjects.1,17 In contrast, the calcification pattern
observed in JAM2 subjects differs to that of other tight
junction genes, as OCLN subjects have band-like calcifica-
tion with simplified gyration6 and JAM3 subjects present
multifocal intraparenchymal hemorrhage, massive cysts,
and subependymal calcification.5
In summary, we show that JAM2 is recurrently mutated
in families with recessive PFBC presenting with a combina-
tion of movement disorder and/or cognitive and psychiat-
ric manifestations. The human phenotype was replicated
in a jam2 KO mouse model. The presence of mutations
in several genes involved in the central NVU presenting
clinically with brain calcification suggests that the NVU
is likely to represent a potential therapeutic target in this
group of disorders.Accession Numbers
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